Analysis Group Researchers Identify Racial Disparities in Treatment of Metastatic Castration-Sensitive Prostate Cancer
Analysis GroupResearchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.